1 |
Coladonato JA, Frankenfield Dl, Reddan DN et al., Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol 2002; 13: 1288-1295.
DOI
ScienceOn
|
2 |
김성남, 최규복. 혈액투석 환자에서 투석 적절도와 빈혈과의 관계. 대한신장학회지 2003; 22(4): 420-425.
|
3 |
IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37(1 Suppl 1): S182-238.
DOI
|
4 |
Miyake T, Kung CK-H, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252(15): 5558- 5564 .
|
5 |
Jacobs K, Shoemaker C, Rudersdorf R et al., Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985; 313: 806-810.
DOI
ScienceOn
|
6 |
송현용, 윤향숙, 강신욱 et al., 말기 신부전 환자에서 투여 경로에 따른 유전자 재조합 인 Erhthropoietin ( ) 의 효과와 안정성에 대한 연구. 대한신장학회지 2002; 21(2): 190-198.
|
7 |
Gregory N. Quality of life in patients on dialysis: Benefits of maintaining a hemoglobin of 11 to 12 g/dL. Nephrol Nurs J 2005; 32(3): 307- 310.
|
8 |
건강보험심사평가원 홈페이지. http://www.hira.or.kr/ (최종 방문일 2009/11/25)
|
9 |
Eschbach JW, Varma A, Stivelman JC. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia? Nephrol Dial Transplant 2002; 17 (Suppl 5): 2-7.
|
10 |
Macdougall IC. Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 1997; 10: 607-614.
|
11 |
Tonelli M, Blake PG, Muirhead N. Predictors of erythropoietin responsiveness in chronic hemodialysis patients. ASAIO J 2001; 47: 82-85.
DOI
ScienceOn
|
12 |
Ifudu O, Uribarri J, Rajwani I. Adequacy of dialysis and differences in hematocrit among dialysis facilities. Am J Kidney Dis 2000; 36(6): 1166-74.
DOI
ScienceOn
|
13 |
Albitar S, Genin R, Fen-Chong M, Serveaux M-O, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1206-1210.
DOI
|
14 |
Abu-Alfa AK, Cruz D, Perazella MA et al., ACE Inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. Am J Kidney Dis 2000; 35: 1076-1082.
DOI
ScienceOn
|
15 |
Odabas AR, Cetinkaya R, Selccuk Y, Keles S, Bilen H. The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. Panminerva Med 2003; 45(1): 59-62.
|
16 |
Sirken G, Kung SC, Raja R. Decreased erythropoeitin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J 2003; 49(4):422-5.
|
17 |
Muhammd S. Jeffery Leiser, Bruce A. Erythropoietin require-ments increase following hospitalization in end-stage renal disease patients. Am J Nephrol 2001; 21: 390-396.
DOI
ScienceOn
|
18 |
김성남, 최규복. 혈액투석 환자에서 투석 적절도와 빈혈과의 관계. 대한신장학회지 2003; 22(4): 420-425.
|
19 |
권건호, 황경화, 김경수. 혈액투석 환자에서 Erythropoietin 저항성에 영향을 미치는 인자 -혈액투석 환자에서 EPO 저항성. 대한내과학회지 2000; 58(5): 510-515.
|
20 |
조종태, 박영선. 혈액투석 치료를 받고 있는 말기신부전 환자에서 적혈구생성인자에 치료반응이 불량한 환자들의 임상적 특징. 대한신장학회지 2004; 23(1): 128-137.
|
21 |
Kalantar-Zadeh K, McAllister CJ, Lehn RS et al., Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42; 761-773.
|
22 |
Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63-72.
DOI
ScienceOn
|
23 |
Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int 1985; 28: 1-5.
DOI
ScienceOn
|
24 |
Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis 2004; 43(3): 471-478.
DOI
ScienceOn
|
25 |
Gejyo F, Saito A, Akizawa T et al., 2004 Japanese society for dialysis therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial 2004; 8(6):443-459.
DOI
ScienceOn
|
26 |
Ifudu O, Urivarri J, Rajwani I et al., Gender modulates responsiveness to recombinant erythropoietin. Am J Kidney Dis 2001; 38(3): 518-522.
DOI
ScienceOn
|
27 |
Di Iorio BR, Stellato D, De Santo NG, Cirillo M. Association of gender and age with erythropoietin resistance in hemodialysis patients: Role of menstrual status. Blood Purif 2004; 22: 423-427.
DOI
ScienceOn
|
28 |
Zelichowski G, Olszowska A, Lubas A, Walkowicz Z. Influence of parathormone level on the doses of human recombinant erythropoietin in haemodialysed patients. Pol Merkuriusz Lek 2002; 13(77): 373 abstract.
|